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TRANSLATIONAL SCIENCES
Altered Macrophage Polarization Induces 
Experimental Pulmonary Hypertension and Is 
Observed in Patients With Pulmonary Arterial 
Hypertension
Amira Zawia, Nadine D. Arnold, Laura West, Josephine A. Pickworth, Helena Turton , James Iremonger ,  
Adam T. Braithwaite , Jaime Cañedo, Simon A. Johnston , A.A. Roger Thompson , Gaynor Miller,* Allan Lawrie *
OBJECTIVE: To determine whether global reduction of CD68 (cluster of differentiation) macrophages impacts the development 
of experimental pulmonary arterial hypertension (PAH) and whether this reduction affects the balance of pro- and anti-
inflammatory macrophages within the lung. Additionally, to determine whether there is evidence of an altered macrophage 
polarization in patients with PAH.
APPROACH AND RESULTS: Macrophage reduction was induced in mice via doxycycline-induced CD68-driven cytotoxic diphtheria 
toxin A chain expression (macrophage low [MacLow] mice). Chimeric mice were generated using bone marrow transplant. Mice 
were phenotyped for PAH by echocardiography and closed chest cardiac catheterization. Murine macrophage phenotyping 
was performed on lungs, bone marrow–derived macrophages, and alveolar macrophages using immunohistochemical and 
flow cytometry. Monocyte-derived macrophages were isolated from PAH patients and healthy volunteers and polarization 
capacity assessed morphologically and by flow cytometry. After 6 weeks of macrophage depletion, male but not female 
MacLow mice developed PAH. Chimeric mice demonstrated a requirement for both MacLow bone marrow and MacLow 
recipient mice to cause PAH. Immunohistochemical analysis of lung sections demonstrated imbalance in M1/M2 ratio in male 
MacLow mice only, suggesting that this imbalance may drive the PAH phenotype. M1/M2 imbalance was also seen in male 
MacLow bone marrow–derived macrophages and PAH patient monocyte-derived macrophages following stimulation with 
doxycycline and IL (interleukin)-4, respectively. Furthermore, MacLow-derived alveolar macrophages showed characteristic 
differences in terms of their polarization and expression of diphtheria toxin A chain following stimulation with doxycycline.
CONCLUSIONS: These data further highlight a sex imbalance in PAH and further implicate immune cells into this paradigm. 
Targeting imbalance of macrophage population may offer a future therapeutic option.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: heart failure, right ◼ humans ◼ macrophages ◼ models, animal ◼ pulmonary hypertension
P
ulmonary arterial hypertension (PAH) is a complex 
disease characterized by increased pulmonary vascu-
lar resistance due to progressive pulmonary vascular 
remodeling that leads to right ventricular (RV) failure and 
ultimately death.1 Excessive infiltration of inflammatory cells 
has been detected in vascular lesions of both clinical and 
experimental PAH2–6 and correlated with the development of 
pulmonary vascular remodeling.7,8 Macrophages are among 
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the inflammatory cells associated with PAH. Increased num-
bers of CD68+ (cluster of differentiation) macrophages are 
reported within diseased lungs of patients with and in animal 
models of PAH.5,9 However, the exact role for macrophages 
and whether their presence or absence is required for the 
vascular remodeling seen in PAH remains unclear.
Tissue macrophages are a remarkably versatile and 
heterogeneous population of immune cells. Their hetero-
geneity and plasticity is crucial to allow them to perform 
tissue-specific functions by undergoing polarized activation 
toward different macrophage subsets.10 Despite the diver-
sity in the nomenclature of macrophage subsets following 
activation, it is widely accepted that macrophage classifi-
cation could be viewed as a linear spectrum on which M1 
macrophages (classically activated) represent one extreme 
and the M2 macrophages (alternatively activated) repre-
sent the other.11 M1 macrophages produce proinflamma-
tory cytokines and mediate defensive mechanisms against 
invading pathogens such as bacteria and viruses.10,12 Mac-
rophages, generated in response to different stimuli such 
as ILs (interleukins), are designated under the M2 subtype. 
Hence, M2 macrophages are anti-inflammatory and par-
ticipate in debris scavenging, regulate wound healing, and 
have immune regulatory functions.12–15 The imbalance in 
M1 versus M2 phenotypic change has been implicated in 
the development of different pathological conditions such 
as tumors, obesity, and osteoarthritis.16–18
Anatomically, 2 main populations of tissue macro-
phages reside in the lung; the alveolar macrophages (AMs) 
found within the alveolar compartment and the interstitial 
macrophages found within the lung parenchymal tissue. 
In the case of inflammation, both tissue macrophage sub-
types can expand by local proliferation of resident macro-
phages and by the recruitment of monocytes, which then 
differentiate into macrophages.19,20 These different lung 
macrophages have different gene expression profiles fol-
lowing exposure to stimuli such as hypoxia.9 Furthermore, 
specifically in a mouse model of pulmonary hypertension 
(PH), interstitial macrophages have been described to 
switch to an anti-inflammatory phenotype in later disease, 
whereas AMs conserve their proinflammatory phenotype.9
To investigate the role of macrophages in the devel-
opment of PH, previous studies have used clodronate-
containing liposomes to deplete cells of monocyte/
macrophage lineage. In rodent models of hypoxia-induced 
PH, this strategy attenuated pulmonary vascular remodel-
ing3 and reduced pulmonary artery pressure.21 Similarly, 
treatment targeting stromal-derived factors mediated 
recruitment of inflammatory cells, reduced numbers of 
CD68+ macrophages in rats with monocrotaline-induced 
PH, and was associated with improvements in pulmo-
nary hemodynamic measurements and pulmonary arterial 
muscularization.5 However, these models are limited by 
the relative lack of macrophage specificity with a tran-
sient and almost complete loss of macrophages. In this 
current study, we utilized the macrophage low (MacLow) 
transgenic mouse model of inducible CD68+ macro-
phage depletion,15 which utilizes the Tetracycline-On sys-
tem to switch on the expression of the diphtheria toxin A 
chain (DTA) in CD68-positive cells, leading to cell death. 
Using this model, up to a 50% reduction of tissue mac-
rophages has been reported following 2 weeks of doxy-
cycline treatment within the liver, spleen, and bone15,22 
(increasing exposure did not lead to further reduction).
We now demonstrate that macrophage depletion in 
MacLow mice leads to the sex-dependant development of 
PAH in male mice. Utilizing bone marrow (BM) transplant 
to generate chimeric mice, we show loss of macrophages 
in both tissue and the circulation is required to induce PAH. 
PAH phenotype was associated with altered M1/M2 ratio 
Nonstandard Abbreviations and Acronyms
α-SMA α-smooth muscle actin
AM alveolar macrophage
BM bone marrow
BMDM bone marrow–derived macrophages
CD cluster of differentiation
DAPI 4′,6-diamidino-2-phenylindole
HV healthy volunteer
DTA diphtheria toxin A chain
IL interleukin
INF interferon
iNOS inducible NO synthase
LPS  lipopolysaccharide
MacLow macrophage low
MDM monocyte-derived macrophage
NF-κB nuclear factor kappa-B
PAH pulmonary arterial hypertension
PASMC pulmonary artery smooth muscle cell
PDGF platelet-derived growth factor
PH pulmonary hypertension
RV right ventricle
RVESP right ventricular end-systolic pressure
SDF stromal cell derived factor
TNFα tumor necrosis factor alpha
Highlights
• The macrophage low model provides useful models 
to further study their contribution to pulmonary arte-
rial hypertension (PAH).
• Male macrophage low mice develop PAH.
• Altered M1/M2 ratio in the lung of macrophage low 
mice with PAH observed in blood-derived macro-
phages from patients with PAH.
• Macrophage populations may be a future therapeu-
tic target for PAH.
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in male MacLow mice, and an altered polarization capac-
ity was also seen in patient-derived macrophages follow-
ing stimulation in vitro. Conditioned media from MacLow 
macrophages cultured in vitro contained IL-6 and induced 
proliferation of pulmonary artery smooth muscle cells 
(PASMCs). These data collectively further highlight an 
important modifying role of macrophage in the pathoge-
nicity of PAH and suggest that targeting this imbalance in 
macrophage population may be a future therapeutic target.
MATERIALS AND METHODS
Data Availability
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Animals
All animal procedures were approved by the University of Sheffield 
Ethics Committee and the UK Home Office (project license num-
ber 40/3517 and 70/8910) and conducted in accordance with 
the Animal (Scientific Procedures) Act 1986. Double transgenic 
CD68-rtTA-EGFP/tetDTA (MacLow) mice were generated by 
crossing the heterozygous single transgenic mouse CD68-rtTA-
EGFP line with a homozygous tetDTA transgenic line, on an FVB 
background, as described previously.15 To induce macrophage 
depletion in MacLow mice, animals were treated with a doxy-
cycline-containing diet (625 mg/kg; ENVIGO Laboratories, Inc, 
Madison, WI) at a dose of 80 mg/kg body weight.
Hypoxia-Induced PH
For the hypoxia-induced PH model, MacLow mice 12 to 13 
weeks of age were fed either doxycycline-containing diet or 
normal laboratory diet (Teklad Global; ENVIGO) for 2 weeks 
and then either left in normal air or placed in a hypoxic chamber 
(10% of oxygen) for 2 weeks to induce PH.23–25 Doxycycline-
containing diet was continued during this period.
MacLow Model
For the MacLow-induced PAH model, male and female groups 
of MacLow mice aged 12 to 13 weeks were randomized and 
fed doxycycline-containing diet for 6 weeks and housed in nor-
mal air. Single transgenic littermates (tetDTA) were also fed 
doxycycline-containing diet for 6 weeks and used as controls. 
BM Transplant
To generate chimeric mice, recipient control and MacLow male 
mice were given a sublethal single dose of whole-body irradia-
tion equaling 10 Gy (1000 rad). Donor BM cells (5–6×106) 
from male control or MacLow mice aged 5 to 7 weeks were 
administered via tail vein injection.23–26 After 4 to 8 weeks 
of recovery on regular normal laboratory diet, all mice were 
assigned to doxycycline diet for a further 6 weeks to induce 
PAH. As per the previous experiments, the single transgenic 
littermates (tetDTA) were used as controls.
PAH Phenotyping
Operators were blinded to genotype and treatment at the time of 
phenotyping. To assess cardiac size and function, echocardiog-
raphy was performed using the Vevo 770 system (Visual Sonics, 
Toronto, Canada) and the RMV 707B scan head. Mice were 
anaesthetized using 5% v/v isoflurane, 2 L/min oxygen, and then 
placed on a heated platform. Anesthesia was maintained using 
0.5% to 2% v/v isoflurane through oxygen. Measurements were 
taken from the long axis and the short axis as described pre-
viously.23–25 Following echocardiography, left ventricular and RV 
catheterization was performed using a closed chest method. Left 
ventricles and RVs were reached through the right internal carotid 
artery and the right external jugular vein, respectively, and hemo-
dynamic parameters obtained using Millar 1F catheters (SPR-
1030 [right], SPR-1045 [left]; Millar Instruments, Inc, Houston, 
TX) as described previously.23–25 Isoflurane-induced anesthesia 
was maintained throughout the procedure (0.5%–2% v/v iso-
flurane). Data were recorded using the Lab Chart Pro software 
(version 7.0; ADInstruments, Oxfordshire, United Kingdom). RV 
hypertrophy index was calculated by dividing the weight of the RV 
by the weight of left ventricular free wall plus septum.
Collection and Culturing of Mouse Primary Cells
To culture BM cells, tibia and femur bones were harvested from 
male mice and flushed with DMEM. Cells were homogenized, 
centrifuged, and resuspended in culture medium containing 100 
IU/mL penicillin/streptomycin antibiotics, 10% v/v fetal bovine 
serum, and 20 ng/mL M-CSF (macrophage colony-stimulating 
factor). At day 7, mature BM-derived macrophages (BMDMs) 
were obtained. Formation of the mature BMDM was evaluated 
using flow cytometric analysis and fluorophore-conjugated anti-
bodies to detect cells expressing F4/80 and CD68. Morphology 
was assessed by EVOS XL Core (Life Technology) hemocytom-
eter, with ×20 magnification. To isolate AMs, mice were culled 
by anesthetic overdose, and bronchoalveolar lavage fluid was 
obtained through intratracheal instillation of 4×1 mL cold normal 
saline. The pellets were centrifuged and resuspended in RPMI 
1640 (Roswell Park Memorial Institute) media (containing 10% 
fetal bovine serum v/v, 100 IU/mL penicillin/streptomycin) and 
passed through a 35-µm cell strainer and then allowed to adhere 
in the incubator for 2 hours. Isolation of AMs was confirmed 
using flow cytometric analysis as described above.
Isolation of Human Peripheral Blood 
Mononuclear Cells and Culture of Monocyte-
Derived Macrophages
Peripheral blood mononuclear cells were isolated using Ficoll 
density gradient separation method from peripheral blood of 
healthy individuals and patients with PAH following informed 
consent according to the Declaration of Helsinki, with local 
research ethics committee approval and informed writ-
ten consent from all subjects from the Sheffield Teaching 
Hospitals Observational study into Pulmonary Hypertension, 
Cardiovascular and Other Respiratory Diseases (STH-Obs, 
UK REC 18/YH/0441). Twelve males and 12 females 
patients with PAH and 4 male and 5 female healthy volun-
teers (HV) were included in the study (Table). Peripheral 
blood mononuclear cells were cultured in macrophage media 
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containing 10% newborn calf serum for 3 hours before being 
washed and refreshed with macrophage differentiation media 
containing 10% heat-inactivated fetal bovine serum. After 14 
days in culture, the resulted monocyte-derived macrophages 
(MDMs) were assessed using flow cytometry. Morphology was 
assessed by EVOS XL Core hemocytometer and by scanning 
electron microscope.
Immunohistochemistry
Formalin-fixed paraffin-embedded lung sections were stained 
with Alcian blue Elastin Van Gieson and immunostained for 
αSMA (α-smooth muscle actin; 1:150; Dako, M0851), von 
Willebrand factor (1:300; Dako, A0082), NF-κB (nuclear 
factor kappa-B; 1:400; Cell Signaling, D14E12), F4/80 
(1:100; Abcam, ab111101), iNOS (inducible NO synthase; 
1:100; Abcam, ab15323), and CD206 (1:100; R&D Systems, 
AF2535). As isotype control, IgG and IgG2a were used. 
Formalin-fixed paraffin-embedded liver sections were stained 
with anti-F4/80 to confirm macrophage ablation. For immuno-
histochemical and immunofluorescent staining, a standard pro-
tocol was followed. Histological images were visualized using 
a Zeiss multislide scanning microscope (Imager.Z2; Carl Zeiss, 
Ltd) with an Axiocam 506 color camera (Zeiss) for immunohis-
tochemical images and MRm camera (Zeiss) for immunofluo-
rescent images. Slides were scanned sequentially using ×20 
magnification objective lens, and the analysis was performed in 
Zen2 blue edition (Zeiss). For all tissue macrophage quantifica-
tion, positively stained cells were counted in 6 fields of view at 
×200 magnification and normalized to the control group.
Assessment of Pulmonary Vascular 
Remodeling
The degree of remodeling was assessed in small pulmonary 
arteries and arteriole <50 µm in diameter by calculating the 
ratio of the media to the cross-sectional area of the whole ves-
sel in sections stained with αSMA and also by assessing the 
degree of muscularization in sections stained with Alcian blue 
Elastin Van Gieson. Vessels were classified as muscularized 
(double elastic lamina) or nonmuscularized 1 thin elastic lamina 
layer) and then expressed as a percentage of muscularized 
vessels to total pulmonary vessels.23–25
Proliferation Assay
Human PASMCs (658401; Lonza, Basel, Switzerland) were 
subcultured in SmBM containing SmGM-2 SingleQuot Kit 
supplements and growth factors (Lonza) containing penicil-
lin and streptomycin at 37 °C (5% CO2). All experiments were 
conducted with cells between passages 4 and 7. PASMCs 
were seeded into 96-well plates (0.5×104 cells/well) and 
allowed to adhere for 24 hours. Cells were then synchronized 
with growth arrest media (DMEM, 0.2% fetal bovine serum, 
penicillin, and streptomycin) for 48 hours before stimulation. 
PASMCs were then stimulated with BMDM conditioned media 
(from MacLow and control mice) or MDM conditioned media 
(from PAH patients and HV) diluted 2-fold with arrest media. 
PASMCs stimulated with either PDGF (platelet-derived growth 
factor; 25 ng/mL) or arrest media were used as positive and 
negative controls, respectively. Proliferation was assessed after 
72 hours using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega, Southampton, United Kingdom).
TaqMan Polymerase Chain Reaction
Total RNA was extracted from frozen mouse lungs using 
the Maxwell miRNA tissue kit (Promega). Following reverse 
transcription using TaqMan Universal Master Mix II (Applied 
Biosystems), gene expression was measured by performing 
TaqMan polymerase chain reaction using Gene Expression 
MasterMix (Applied Biosystems) for TNFα (tumor necrosis fac-
tor alpha; Mm00443258_m1), CXCL1 (Mm04207460_m1), 
IL-6 (Mm00446190_m1), IL-1β (Mm01336189_m1), and 
IL-10 (Mn01288386_m1) on the 7900HT fast real-time poly-
merase chain reaction system (Applied Biosystems). Gene 
expression was calculated using the ∆∆CT comparative quan-
tification method with 18S rRNA as an endogenous control.
ELISA
Macrophage culture media from mouse BMDM were run using 
assay DY406 (mouse IL-6) as per manufacturer’s instructions 
(R&D Systems).
Table. Demographics and Clinical Characteristics of 
Patients With PAH and HV
Demographics
PAH 
value, % HV
Age, y 53±12 42±5.6
Women/men 12/12 (50/50) 5/4 (56/44)
Ethnicity: White/other 22/2 7/2
Diagnostic group 1 classification 24 NA
 Idiopathic 19 (79) NA
 Heritable (BMPR2) 5 (21) NA
Functional class
 I … NA
 II 2 NA
 III 14 NA
 IV 8 NA
Mean pulmonary artery pressure, 
mm Hg
52.5±13.8 NA
Mean right atrial pressure, mm Hg 11.1±5.3 NA
Pulmonary arterial wedge pressure, 
mm Hg
11.8±5.3 NA
Cardiac index, L/min per m2 2.5±0.8 NA
Pulmonary vascular resistance 
(dynes·s·cm−5)
826.9±509.2 NA
PAH-related therapy
 Endothelin receptor antagonist 9 (37.5) NA
 Phosphodiesterase 5 inhibitor 4 (16.6) NA
 Prostaglandin 3 (12.5) NA
 Calcium channel blocker 1 (4.2) NA
BMPR2 indicates bone morphogenetic protein receptor (type 2); HA, healthy 
volunteers; NA, not available; and PAH, pulmonary arterial hypertension.
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Dot Blot Technique for Detection of DTA Protein 
Expression
For the dot blot experiment, a narrow-mouth pipette tip was 
used to spot 2 µL of cell lysate (normalized for protein con-
centration, Pierce 660nm Protein Assay) onto a nitrocellulose 
membrane (Amersham Protran 0.45 µm NC). The membrane 
was left to dry for few minutes and then soaked in blocking 
buffer (30% Odyssey blocking buffer, diluted in PBS; LI-COR) 
before incubation with anti-DTA antibody (1:2000; Abcam, 
ab8308). Liver tissue harvested from MacLow mouse that had 
been treated with doxycycline for 2 weeks was used as a posi-
tive control. The membrane was visualized by the Odyssey SA 
imaging system (LI-COR Biosciences).
Statistical Analysis
No data were excluded from the analysis. All statistics were 
performed using Prism (version 8.4.2 for Mac; GraphPad 
Software, San Diego, CA). Statistical comparison between the 
different groups was established by the use of 1-way ANOVA. 
However, due to sample size, the normality and variance were 
not tested to determine whether the applied parametric tests 
were appropriate. Post hoc analysis was performed using 
Benjamini, Krieger, and Yekuteli 2-stage linear step-up correc-
tion where >4 comparisons were made or by Bonferroni where 
<4. Values are presented as mean±SEM, and differences of 
P<0.05 values were accepted as significant.
RESULTS
Reduction of CD68 Cells Has No Effect on 
Hypoxia-Induced PH
To determine whether macrophages are required 
for pulmonary vascular remodeling associated with 
hypoxia-induced PH, double transgenic CD68-rtTA-
EGFP×tetDTA, MacLow mice were fed either doxycy-
cline-containing diet (to induce macrophage depletion) 
or normal laboratory diet (chow) for 2 weeks. PH was 
then induced by hypoxia (10% oxygen) for further 2 
weeks with continuous administration of doxycycline 
diet (parallel groups were left in room air as controls; 
Figure 1A). In both normoxia and hypoxia, doxycycline 
treatment reduced the total number of F4/80+ mac-
rophages within the liver to about 50% compared with 
untreated control livers (Figure 1B and 1I). However, this 
had no effect on the hypoxia-induced increase in RV 
end-systolic pressure (RVESP; Figure 1C), RV hyper-
trophy (Figure 1D), or pulmonary vascular remodel-
ing (Figure 1E and 1I). Additionally, we observed that 
MacLow mice treated with doxycycline but not exposed 
to hypoxia showed a trend toward higher RVESP (Fig-
ure 1C) and increased pulmonary vascular remodeling 
(Figure 1E). To determine the ablation of lung macro-
phages following the 4-week doxycycline treatment, 
anti-F4/80, anti-iNOS, and anti-CD206 were used to 
quantify M total, M1, and M2, respectively. Within the 
lung tissue, there was a significant increase in the total 
number of F4/80+ macrophages following exposure 
to hypoxia of nondoxycycline-treated mice compared 
with the normoxia group (Figure 1F and 1I). Doxycycline 
treatment reduced the number of F4/80+ macrophages 
in both the normoxia and hypoxia groups to a similar and 
significant level. Quantification of macrophage subtype 
showed no significant reduction in iNOS+ macrophages 
(M1; Figure 1G) or in CD206+ macrophages (M2; Fig-
ure 1H) in doxycycline-treated groups compared with 
correspondent controls.
It was unexpected to report that MacLow mice treated 
with doxycycline only for 4 weeks showed a trend toward 
higher pressure, and by further examination, it seems 
that this trend was driven by the male (♂) mice, sug-
gesting a potential link between sex, macrophage loss, 
and the development of PH. To explore this further, we 
examined whether a longer period (6 weeks) of mac-
rophage depletion would result in a more pronounced 
spontaneous PH phenotype and whether this remained 
sex dependent.
Reduced CD68 Macrophage Number Causes 
Pulmonary Vascular Remodeling and PAH in 
Male but Not Female MacLow Mice
Male and female MacLow and control (single transgenic) 
mice were treated with doxycycline for 6 weeks in nor-
moxic conditions with no other insult (Figure 2A). As 
with the previous experiment, a significant reduction of 
F4/80+ macrophages was confirmed in the liver (Fig-
ure 2B). Interestingly, only male MacLow mice developed 
a significant increase in RVESP (Figure 2C) compared 
with male controls. This increase in RVESP was also 
associated with an increase in RV hypertrophy (Fig-
ure 2D). There was no significant effect on either cardiac 
index (Figure 2E) or left ventricular end-systolic pres-
sure (Figure 2F), but there was evidence of significant 
pulmonary vascular remodeling (Figure 2G through 2I). 
Immunohistochemical analysis of NF-κB transcription 
factor demonstrated expression within the remodeled 
small pulmonary arterial lesions in MacLow lung sections 
(Figure 2I). Collectively, we showed here that increasing 
doxycycline treatment period from 4 to 6 weeks caused 
a more pronounced sex-specific spontaneous PAH phe-
notype, which suggests that reduction in CD68+ macro-
phages can lead to spontaneous PAH phenotype in male 
MacLow mice.
Imbalance in M1/M2 Ratio Is Associated With 
the Development of PAH in Male MacLow Mice
To assess the level of ablation of lung macrophages, 
immunohistochemical analysis of F4/80, iNOS, and 
CD206 was performed to quantify total, classically acti-
vated (M1) macrophage and alternatively activated (M2) 
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Figure 1. Loss of CD68+ (cluster of differentiation) macrophages does not protect against hypoxia-induced PH: macrophage 
low (MacLow) mice were fed either doxycycline-containing diet or normal laboratory diet for 2 wk to induce macrophage 
ablation, and then PH was induced by hypoxia (10% oxygen) for another 2 wk with continuous doxycycline diet.
Parallel groups were left in normal air as controls. A, Experimental timeline. B, Quantification of F4/80+ macrophages remaining within the liver 
after 4-wk doxycycline treatment. C–E, Assessment of PH phenotype with right ventricular (RV) end-systolic pressure (Continued )
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macrophage number, respectively. Significant reduction 
in total lung macrophages was observed in both male 
and female MacLow mice undergoing doxycycline treat-
ment compared with controls (Figure 3A and 3E), with 
no significant difference between male and female mice. 
Further characterization of macrophage subtype showed 
a significant reduction in iNOS+ macrophages (M1) in 
the lung of both male and female MacLow mice (Fig-
ure 3B and 3E). However, CD206+ (alternatively acti-
vated M2) macrophages were significantly reduced in 
the lungs of only female MacLow mice (Figure 3C and 
3E). Comparison of the M1/M2 ratio (Figure 3D and 
3E) highlighted an imbalance between the M1/M2 ratio 
in only the male MacLow mice suggesting that this is 
critical to driving the PAH phenotype. Despite reduced 
numbers, F4/80+ macrophages were observed accu-
mulating within the thickened media of distal pulmonary 
arterioles of male MacLow mice with PAH (Figure 3F). 
To investigate whether the altered macrophage accu-
mulation in the pulmonary arterioles was also associated 
with altered cytokine expression within the lung tissue, 
we measured the gene expression of TNFα, CXCL1, 
IL-6, IL-1β, and IL-10, although there was no significant 
increase in the expression of either cytokine (Figure I in 
the Data Supplement).
MacLow BM Cells Alone Are Not Sufficient to 
Induce PAH
Next, we investigated whether depletion of the tissue or 
BMDM population was sufficient to induce PAH in male 
mice. BM transplant of male MacLow and control (single 
transgenic) mice was performed to generate chimeric 
mice (Figure 4A). Following engraftment (4–9 weeks) 
and 6 weeks of doxycycline treatment, macrophage 
depletion was confirmed in the livers of MacLow recipi-
ent mice (Figure 4B). Assessment of PAH phenotype 
identified that only MacLow recipient mice with MacLow 
BM developed PAH as defined by an increased RVESP 
(Figure 4C) and pulmonary vascular remodeling (media/
cross-sectional area; Figure 4D and 4J). There was no 
significant increase in RV hypertrophy (Figure 4E). These 
data imply that depletion of both BMDMs and lung-res-
ident macrophages is required for the development of 
PAH in this model. Analysis of lung macrophage popula-
tions demonstrated a similar reduction to those previously 
observed in total F4/80 macrophages (Figure 4F) and 
iNOS+ macrophages (Figure 4G) in MacLow recipients, 
but as previously observed, the CD206+ macrophage 
numbers were preserved (Figure 4H). As with previous 
experiments, there was a significant reduction in the M1/
M2 ratio in the MacLow recipient mice with MacLow BM 
that developed PAH when compared with controls (Fig-
ure 4I). Remodeled pulmonary arterioles demonstrating 
increased smooth muscle cell content also demonstrated 
NF-κB expression (Figure 4J). Although there was no 
significant increase in inflammatory cytokine expression, 
there was a trend for increased expression of IL-6 in 
MacLow to MacLow group that developed PAH (Figure 
II in the Data Supplement).
Doxycycline Treatment In Vitro Leads to 
Macrophage Polarization Toward M2 Subtype in 
MacLow-Derived Macrophages
Since the PAH phenotype developed in male MacLow 
mice, we investigated the polarization capacity of 
MacLow-derived macrophages in vitro. Male MacLow 
BMDMs and control BMDMs were stimulated with 
cytokines or doxycycline before assessing cell surface 
marker expression to characterize M1 and M2 pheno-
type. No significant differences were detected in the 
basal expression of CD68 and F4/80 or M1/M2 mark-
ers in BMDM between untreated MacLow (not treated 
with doxycycline) and control mice (data not shown). 
Similarly, there was no significant difference between 
the expression profile of MacLow- and control-derived 
BMDM stimulated in vitro with either lipopolysaccha-
ride (100 ng/mL) and IFNγ (50 ng/mL) for M1 activa-
tion or IL-4 (10 ng/mL) for M2 activation (Figure 5A). 
Interestingly, MacLow-derived macrophages stimulated 
with low dose of doxycycline (1 µg/mL) induced dif-
ferentiation toward the alternatively activated M2 mac-
rophage subtype as shown by increased expression of 
CD206+F4/80+ compared with untreated MacLow-
derived cells (Figure 5A). A higher dose of doxycy-
cline (5 ug/mL) demonstrated a significant increase in 
CD206+F4/80+ expression in MacLow-derived BMDM 
that was not observed in control BMDM (Figure 5B). This 
increase in polarization toward the alternatively activated 
M2 phenotype was comparable to that observed when 
stimulating either control or nondoxycycline-treated 
MacLow BMDM with IL-4 (canonical M2 driver). These 
observations were also supported by the morphological 
assessment of doxycycline-treated cells as they were 
elongated, and their morphology strongly resembles the 
M2 morphology (Figure 5A).
Figure 1 Continued. (RVESP; C), RV hypertrophy (RVH) index (D), and medial wall thickness as a ratio of total vessel size (media/cross-
sectional area [CSA]; E). F–H, Quantification of macrophages remaining within the lung after 4-wk doxycycline treatment using anti-F4/80 
antibody for total macrophages (F), anti-iNOS (inducible NO synthase) antibody for M1 macrophages (G), and anti-CD206 antibody for M2 
macrophages (H). I, Representative photomicrographs of liver sections immunostained for F4/80 and lung sections immunostained for F4/80 
and αSMA (α-smooth muscle actin) or stained with Alcian blue Elastic van Gieson (ABEVG). n=6 to 10/group. Bars show mean±SEM. 
Hypoxia, 10% oxygen; normoxia, 21% oxygen. ♂, male mice; ♀, female mice. Scale bar=50 µm. LV&S indicates left ventricular free wall plus 
septum. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 2. Loss of CD68+ (cluster of differentiation) macrophages causes PH in male macrophage low (MacLow) mice: male and 
female groups of MacLow or control mice were fed doxycycline-containing diet for 6 wk.
A, Experimental timeline. B, Quantification of F4/80+ macrophages remaining within the liver following 6-wk doxycycline treatment. Assessment 
of PH phenotype was shown by (C) right ventricular (RV) end-systolic pressure (RVESP), (D) RV hypertrophy (RVH) index, (E) cardiac index, 
(F) left ventricular end-systolic pressure (LVESP), (G) medial wall thickness as a ratio of total vessel size (media/cross-sectional area [CSA]), 
and (H) pulmonary vascular remodeling as percentage muscularized vessels. I, Representative photomicrographs of lung sections stained 
with Alcian blue Elastic van Gieson (ABEVG) or immunostained for VWF (von Willebrand factor), αSMA (α-smooth muscle actin), and NF-κB 
(nuclear factor kappa-B) from male and female groups. Bars show mean±SEM. ♂, males; ♀, females. Scale bar=50 µm. LV&S indicates left 
ventricular free wall plus septum. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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To investigate whether these phenotypic changes in 
BMDM were also observed in AM, AMs were isolated 
by bronchoalveolar lavage and stimulated with 5 µg/mL 
doxycycline for 48 hours as described above. In contrast 
to the BMDM, the expression of CD68 was found to be 
low in AMs from both MacLow and control mice, and 
no significant difference in the expression of CD68 or 
CD206 was observed following doxycycline stimulation 
(Figure 5C). These data suggest that the AM may be 
less susceptible to cell death via the CD68-driven DTA 
in the MacLow model due to lower expression levels of 
CD68. To test this, and the dependence of the MacLow 
system on CD68 for DTA expression, we assayed pro-
duction of DTA by AMs following doxycycline stimulation 
Figure 3. Imbalance in M1/M2 ratio is associated with the development of pulmonary arterial hypertension in male 
macrophage low (MacLow) mice: male and female groups of MacLow or control mice were fed doxycycline-containing diet.
Quantification of the number of macrophages remaining within the lung after 6 wk was performed using (A) anti-F4/80 antibody for total 
macrophage count, (B) anti-iNOS (inducible NO synthase) antibody for M1 macrophages, and (C) anti-CD206 (cluster of differentiation) 
antibody for M2 macrophages. D, M1-to-M2 ratio. E, Lung sections stained with antibodies against F4/80, iNOS, and CD206 and 
counterstained with hematoxylin in the MacLow-induced PH model. F, Representative immunofluorescence images of paraffin-embedded 
lung sections stained with anti-F4/80 (red) and SMA (smooth muscle actin; yellow) with cell nuclei labeled with DAPI (4′,6-diamidino-2-
phenylindole; blue). Images were captured using a Zeiss multislide scanning microscope at ×20 magnification. Bars show mean±SEM. ♂, 
males; ♀, females. Scale bar, 50 µm. *P<0.05.
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Figure 4. Macrophage low (MacLow)–derived bone marrow (BM) cells alone are not sufficient to induce PH in control mice: 
male BM chimeras were generated and fed with doxycycline-containing diet for 6 wk following a recovery period.
A, Generation of male chimeric mice by BM transplant. B, Quantification of the number of F4/80+ macrophages remaining within the 
liver following 6-wk doxycycline treatment. Assessment of PH phenotype in male chimeric mice was performed using (C) right ventricular 
(RV) systolic pressure (RVSP) and (D) medial wall thickness as a ratio of total vessel size (media/cross-sectional area [CSA]). E, Right 
ventricular hypertrophy (RVH) index. Quantification of the number of macrophages remaining within the lung following 6-wk doxycycline 
treatment was performed using (F) anti-F4/80 antibody for total macrophage count, (G) anti-iNOS (inducible NO synthase) antibody for 
M1 macrophages, and (H) anti-CD206 (cluster of differentiation) antibody for M2 macrophages. I, M1-to-M2 ratio. J, Representative image 
of immunofluorescence staining (top) for anti-SMA (smooth muscle actin; red) and the cell nuclei labeled with DAPI (4′,6-diamidino-2-
phenylindole; blue) and immunohistochemical staining (bottom) for anti–NF-κB (nuclear factor kappa-B). ♂, males. Bars show mean±SEM. 
Scale bar=50 µm. LV&S indicates left ventricular free wall plus septum; and RVESP, right ventricular end-systolic pressure. *P<0.05, **P<0.01.
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Figure 5. Doxycycline treatment in vitro lead to skew macrophage polarization toward M2 subtype.
A, Representative flow cytometry scatter plots of bone marrow–derived macrophages (BMDMs) following culture and stimulation using anti-F4/80 
vs anti-CD68 (cluster of differentiation; for nontreated), anti-CD86 (for LPS [lipopolysaccharide]/INF [interferon]-γ treated), and anti-CD206 (for 
IL [interleukin]-4 and doxycycline treated), with representative images of the corresponding morphology of macrophage low (MacLow)–derived 
macrophage population. B, Bar graph comparing the percentage of CD206+F4/80+ BMDM following stimulation with doxycycline alone (nontreated, 
NT) to doxycycliine and IL-4 (IL-4). Bars represent mean±SEM from 3 independent experiments. C, Representative flow cytometry scatter plot of 
alveolar macrophages (AMs) following harvesting and stimulation using anti-F4/80 vs anti-CD68 (for nontreated) and anti-CD206 (for doxycycline 
treated). D, Dot plot analysis using anti-DTA antibody comparing the level of expression of DTA protein between BMDM and AM following doxycycline 
stimulation in vitro. Protein extracted from the liver of a MacLow/doxycycline-treated mouse was used as a positive control. *P<0.05.
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in vitro. The expression of DTA was confirmed in cells 
isolated from MacLow liver (positive control; Figure 5D); 
however, a much lower expression of DTA was observed 
in MacLow BMDMs and less still in AM following doxy-
cycline treatment (Figure 5D). These data suggest, rela-
tive to circulating sources of macrophages, AM would be 
less susceptible to doxy-induced killing via CD68-driven 
expression of DTA.
Finally, to determine whether the polarized MacLow 
macrophages could potentially impact on pulmonary vas-
cular remodeling, we treated PASMC proliferation with 
conditioned media from MacLow and control BMDMs in 
vitro. We found that conditioned media from doxycycline-
treated MacLow BMDMs but not control mouse–derived 
BMDMs stimulated PASMC proliferation (Figure 6A). 
Unlike BMDMs, conditioned media from AMs was unable 
to induce PASMC proliferation in vitro (data not shown). 
To determine whether tissue IL-6 levels could, in part, 
arise from the MacLow macrophages, we measured IL-6 
levels in BMDM culture media following treatment with 
doxycycline by ELISA. We found that IL-6 was signifi-
cantly higher in MacLow-derived BMDMs compared with 
control BMDMs (Figure 6B).
MDMs From PAH Patients Show Reduced M2 
Polarization Potential Following Activation With 
IL-4
After demonstrating that reducing numbers of CD68+ 
macrophages in MacLow mice led to M1/M2 imbal-
ance, we next sought to determine whether there was 
evidence of an altered M1/M2 ratio in blood-derived 
macrophages from patients with PAH. Peripheral 
blood mononuclear cells isolated from HV and patients 
with PAH were cultured to generate MDMs and then 
stimulated to induce M1 or M2 polarization using 50 ng/
mL INF (interferon)-γ+ 100 ng/mL lipopolysaccharide 
or 20 ng/mL IL-4, respectively. Morphological assess-
ment of MDMs revealed that unstimulated macrophages 
(M0) exhibited a round shape, M1 macrophages pre-
dominantly retained this shape, while the majority of 
M2 macrophages developed a spindle-like appearance 
(Figure 7A). Evaluation of polarization markers in M0, 
M1, and M2 was performed by flow cytometric analysis 
using fluorophore-conjugated antibodies to detect cells 
expressing CD11b, CD80, and CD206 (Figure 7B). In 
MDMs from patients with PAH or HV, we confirmed 
the increase in expression of the M1 marker (CD80) in 
polarized M1 MDMs (≈65%) in comparison with resting 
M0 (Figure 7C). However, while there was a significant 
increase in expression of the M2 marker (CD206) fol-
lowing IL-4 stimulation in MDMs from HV (Figure 7D), 
this was not observed in MDMs from patients with PAH 
(Figure 7D). Similar to the observations from the MacLow 
mice, this also resulted in a skew in the M1/M2 ratio. 
Since conditioned media from male MacLow BMDMs 
caused proliferation of PASMCs in vitro, we next inves-
tigated whether conditioned media from human MDMs 
differentiated toward the M2 phenotype would similarly 
induce PASMC proliferation. Conditioned media was 
collected from both HV and PAH isolated MDM fol-
lowing stimulation with IL-4, applied to PASMCs, and 
cell proliferation assessed. Similar to the MacLow mice 
BMDM, M2-MDM conditioned media induced prolifera-
tion in PASMC; however, there was no significant differ-
ence between media harvested from HV or patients with 
PAH (Figure 7E).
Figure 6. Doxycycline treatment in vitro induces PASMC proliferation and IL (interleukin)-6 release.
A, Proliferation of PASMCs following stimulation with BMDM culture media for 72 h; BMDMs from control and macrophage low (MacLow) 
mice were pretreated with doxycycline for 48 h, presented as fold increase. B, IL-6 was measured in BMDM culture supernatant following 
doxycycline treatment for 48 h using ELISA. Box and whisker plots represent the interquartile range (box) with the line representing the median 
and whisker, the full range of the data. PDGF indicates platelet-derived growth factor. *P<0.05, **P<0.01.
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DISCUSSION
Inflammation and the recruitment of inflammatory cells 
are regarded as playing a key role in the pathogenesis of 
PAH; however, the specific role of individual cell popula-
tions remains unclear. In this study, we demonstrate that 
macrophage number increases within the lung following 
hypoxia (as reported previously2–4). Perhaps counterintui-
tively, we found an association between the reduction of 
CD68+ macrophages and development of PAH in male 
but not female MacLow mice. Through the use of chi-
meric mice, we demonstrated that both MacLow tissue 
and MacLow BM is required to produce the PAH phe-
notype. BMDMs from male MacLow mice that develop 
PAH have skewed M1/M2 ratio, release IL-6, and induce 
proliferation of PASMC in vitro. Similarly, MDMs derived 
from patients with PAH also showed impaired polariza-
tion toward M2 subtype following IL-4 stimulation and 
Figure 7. Monocyte-derived macrophages from pulmonary arterial hypertension (PAH) patients show impaired M2 polarization 
potential following activation with IL (interleukin)-4.
A, Representative microscopy images show the morphology of mature and polarized monocyte-derived macrophages (MDMs) from patients with 
PAH. Qualitative assessment of morphology was performed by light microscopy with ×20 magnification (large panels) and by scanning electron 
microscopy for higher magnification images of individual cells (small panels/scale bar=10 µL). B, Representative flow cytometry scatter plots of 
MDMs following culture and stimulation using anti-CD11b (cluster of differentiation) vs anti-CD80 and anti-CD206. C, Box plot represents the 
percentage of CD80+ population in M0 and M1 macrophages derived from patients and healthy volunteers (HV). D, Box plot represents the 
percentage of CD206+ population in M0 and M2 macrophages derived from patients and HV. E, Proliferation of PASMCs following stimulation 
with MDM culture media for 72 h. Box and whisker plots represent the interquartile range (box) with the line representing the median and whisker, 
the full range of the data. INF indicates interferon; ns, nonsignificant; and PDGF, platelet-derived growth factor.
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altered M1/M2 balance similar to that observed in the 
male MacLow mice with PAH, and similar to MacLow 
cell, conditioned media was able to induce proliferation 
of PASMC in vitro. These data further support a modula-
tory role of macrophages in PAH.
To our knowledge, this is the first demonstration that 
specific CD68+ macrophage depletion using this trans-
genic approach leads to the development of PAH in an 
animal model. Previous ablation strategies have used 
nonspecific intravenous3 or intratracheal administration21 
of liposomes containing clodronate (Cl2MBP) to deplete 
monocyte/macrophage number or therapeutic inhibition 
of SDF (stromal cell derived factor)-1 to inhibit the pul-
monary vascular infiltration of CD68+, CD3, and mast 
cells in the monocrotaline rat model of PH.5 Interestingly, 
none of these studies reported a spontaneous increase 
in pulmonary pressure or associated remodeling in the 
normoxic control animals after macrophage depletion. 
This suggests that each macrophage depletion strategy 
may target different macrophage populations.
During the acute phase of inflammation, macro-
phages adopt a classical activated M1 phenotype driv-
ing the release of proinflammatory mediators. However, 
regulation of this must be controlled to prevent tissue 
damage, and switching toward the anti-inflammatory 
M2 phenotype helps mediate wound healing and tissue 
repair. An imbalance of M1 and M2 and switching back 
and forth may induce pathological consequences.13,27,28 
The MacLow-induced PAH phenotype was associated 
with a decrease in M1/M2 ratio but with the presence of 
M2 macrophages within the lungs, consistent with previ-
ous literature.4,29 This may, in part, be due to the surviving 
macrophages switching their phenotype to the M2 alter-
native activation state to clear up the dead cells and cell 
debris.14 However, given the sex specificity of the skew-
ing toward more M2 macrophages in the lungs of male 
MacLow mice and the PAH phenotype observed only 
under these conditions, it may be reasonable to assume 
a certain degree of causality. Data from the MacLow 
mouse data demonstrate an imbalance in M1/M2 ratio 
that was driven by a predominance of M2 macrophages 
in the lung. In contrast, MDM samples collected from 
patients with PAH demonstrated an impaired M2 polar-
ization following stimulation with IL-4 in vitro. Although 
the imbalance in macrophage population is generated 
differently, both result in a skewed proportion of M1 to 
M2 macrophages. However, caution should be taken in 
directly extrapolating results from mice to humans, and 
in particular, the comparison of transgenic depletion of 
macrophages with a toxin in vivo, with the differentiation 
of blood-derived macrophages in vitro. Our study also 
proposes a link between M2 phenotype, IL-6, NF-κB, 
PASMC proliferation, and pathogenesis of PAH. This is 
in keeping with previous studies that demonstrated that 
lung-specific overexpression of IL-6 in transgenic mice 
is sufficient to induce pulmonary vascular remodeling 
and PH via a pro-proliferative mechanism.8 Furthermore, 
IL-6 release has been shown to induce M2 accumulation 
within the lung29 and influence the M1/M2 phenotypic 
change in dermatitis30 and colorectal tumors.31
Transplanting MacLow-derived BM into control ani-
mals was not sufficient to induce PAH emphasizing the 
contribution of lung-resident macrophages in the phe-
notype, although the milder phenotype observed (most 
likely due to the irradiation) made it difficult to interpret. 
It is still not completely known what happens to resident 
tissue macrophages in the lung after irradiation, but the 
removal of local stem cells residing in the alveolar spaces 
has previously been reported.32
Our data also highlight a potential inflammatory mech-
anism to contribute to the sex imbalance in PAH. Sex 
bias is well documented in both clinical and experimental 
forms of PH. In human disease, PAH is female dominant 
(4.1:1 female-to-male ratio in idiopathic PAH subcate-
gory).33 However, men present with more severe disease 
with worse RV function and poorer survival33–35; however 
in contrast, in some animal models, the female sex has 
been shown to produce a less severe phenotype.36–38 
The mechanisms behind this sex difference in PAH prev-
alence and survival are unclear and have resulted in the 
so-called sex paradox in PAH, focusing largely on the 
role of sex hormones.39–41 However, sex hormones alone 
fail to explain the sex paradox as conflicting findings also 
correlate female sex, estrogen, and estrogen metabolites 
to the development of PAH.42–44 This suggests that other 
factors must contribute to increasing the susceptibility to 
PAH. Studies of nonhormonal factors such as XY chro-
mosome showed that hypoxic XY male developed less 
severe PH regardless of gonadal sex compared with XX 
mice.45 Moreover, regulatory T cells have a well-known 
role in controlling self-tolerance, and abnormal regula-
tory T-cell numbers have been reported in patients with 
PAH.46 More recently, regulatory T-cell function has 
been linked to the sex paradox in PAH with regulatory 
T-cell function shown to be a critical protective mecha-
nism against pulmonary vascular remodeling in female 
rodents.46 On a cellular level, in vitro characterization of 
human- and mouse-derived macrophages showed no 
sex difference in polarization of macrophages.
Collectively, this study further highlights the impor-
tant role that sex may play in the pathogenesis of PAH 
and further supports the concept that inflammation may 
be a contributing factor to this. The MacLow model 
provides a useful alternative to previous macrophage 
depletion models to further study their contribution to 
PAH and pulmonary vascular remodeling. Targeting this 
imbalance of macrophage population may be a future 
therapeutic target.
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